Methods: ISMAR is an international, multicenter, non-interventional and cross-sectional study conducted in adults and children ($6 years) with physicians-diagnosed AR from 11 countries (Egypt, Mexico, Brazil, Colombia, Guatemala, Iran, Venezuela, Argentina, Israel, Kuwait, United Arab Emirates). Doctors from 4 specialties were required in each country: (i) GPs/ Family doctors/internists, (ii) pediatricians, (iii) allergologists/pulmonologists, and (iv) ENT. They were invited to participate in the study from master lists of physicians attending patients with AR in their respective countries and answered the Doctor Questionnaire that included questions about guidelines awareness, relevant AR symptoms, and preference for prescribing medication, among others. Results: Two hundred and thirty four physicians participated in the study. Most of them were awared about ARIA (82.5%), GINA (71.4%). They followed guidelines recommandations to classify patients severity (84.2%) and for choosing the treatment accordingly (84.6%). Key symptoms to make AR diagnosis were: congestion (84.8%), sneezing (79.1%), anterior watery rhinorrhea (75.9%). SQ and AR severity were assessed mainly by clinical history (97.1% and 98%). The main reasons to prescribe medication were: symptom severity/frequency (97.9%), drug efficacy (85.9%) and safety (76.5%). Other less relevant raisons were: personal experience (65%), cost (55.1%) and frequency of dosages (54.7%). The preferred medications were oral antihistamines (OH1A) and intranasal corticosteroids (INC) [5 in a 0-5 scale]. Other treatments (oral decongestants, leukotriene antagonists, SCIT/SLIT), among others were considered as second level in preference. Conclusions: Guidelines are well known and useful to physicians. Clinical history was the main way to evaluate the patient's sleep quality, classification, severity and election of treatment. Objective measures for assessment were scarcely used. OH1A and INC were the most widely recommended treatment for AR and were considered effective and safe. 2 Sanofi, Paris, France. Background: Allergic Rhinitis (AR) is a worldwide spread illness and has an important impact on social life, sleep quality, school and work productivity and huge direct and indirect costs. Patient preference is becoming an important aspect in medical care. ISMAR was designed as the first-over global survey to identify differences in attitudes and preference in patients and physicians about AR. This study shows the patient's view. Methods: ISMAR is an international, multicenter, non-interventional and cross-sectional study conducted in adults and children ($ 6 years) with physician diagnosis-AR of at least 1 year of duration. Physicians recruited consecutive patients to whom the ISMAR questionnaire was administered. The study data collection was performed during a single visit. Other 2 additional documents (the investigator's questionnaire and Case Record Form) were also filled in. Results: A total of 2776 patients from 11 countries were evaluated. Patient's demographics were the following: mean age 31 years, gender (F) 54%; urban residence (86.1%), suburban (6.6%) and rural (4.9%). The main co-morbidities were: sinusitis (50%), asthma (33%), conjunctivitis (36%), otitis (13%) and nasal polyps (11%). Nasal symptoms were associated to house-dust mites (84%), moulds (33%) animal dander (31%) and pollens (41%) exposure. At least one current treatment was received in 91%, and recommendation to avoid allergens or irritants in 93% of patients. 80% the patients had received oral anti-H1 antihistamines (OH1A), 66% intranasal corticosteroids (INC), 63% oral/intranasal decongestants and 14% sub-cutaneous specific immunotherapy (SCIT). The patients' preference was the following: oral route of administration, 51%; and intranasal route 28%. The patients' preference mediations were: OH1A, 76%; INC, 49%; and SCIT 12%. Main factors affecting treatment compliances were cost (32%), fear of Adverse Events reported (18%) and frequency of doses (34%). Taking into account patients' education, 85% of them received oral explanation on disease and only 51% written indications. Conclusions: OH1A and INC were the most widely used treatments for rhinitis and were considered safe and effective. The majority of patients preferred the oral route. Written educational material given to patients is scarce. These might be taken into account to enhance treatment adherence and outcomes. 2 Medicine, Nova Southeastern University, Ft. Lauderdale, FL. Background: Although allergen-specific immunotherapy (SIT) is the only disease-modifying treatment currently available for allergic rhinitis (AR), few potentially appropriate United States patients initiate or sufficiently adhere to treatment. 1,2 We compared SIT initiation and adherence between AR-diagnosed children and adults. Methods: Selected were child (age ,18 years) and adult (age $18 years) Florida Medicaid enrollees (1997)(1998)(1999)(2000)(2001)(2002)(2003)(2004)(2005)(2006)(2007)(2008)(2009)) with newly-diagnosed AR (no AR claim within 1 year preceding the first identified AR diagnosis) who received de novo SIT (no SIT preceding the first AR diagnosis), had $4 years of follow-up from first AR diagnosis, and 6 months of follow-up from first SIT administration. T tests, Wilcoxon signed-rank tests, and chi-squares compared differences between children and adults. Results: Overall, 8% (330,993/4,193,986) of children and 3% (105,380/ 3,330,245) of adults received $1 AR diagnosis (P , 0.0001). Among these, 2,913 children and 1,332 adults met study criteria. Adults were 3.6 times more likely than children to immediately initiate SIT (ie on the date of their first AR diagnosis) (OR 3.6, 95 % CI, 3.1-4.2, P , 0.0001); children were twice as likely as adults to receive SIT $1 year from the first AR diagnosis (OR 2.2, 95 % CI, 1.9-2.6, P , 0.0001). The median number of SIT administrations was 13 for children and 5 for adults (P , 0.0001). Fourteen percent of children and 20% of adults discontinued SIT after 1 administration; 33% of children and 52% of adults discontinued after 5 administrations. Adults were 1.6 and 2.3 times more likely than children to discontinue SIT following 1 only administration (OR 1.6, 95% CI, 1.3-1.9, P , 0.0001) and 5 administrations (OR 2.3, 95% CI, 2.0-2.6, P , 0.0001), respectively. Conclusions: Although adults were significantly more likely to immediately initiate SIT, they were also significantly more likely to discontinue treatment within the first 5 administrations. These preliminary findings may guide development of future patient-specific interventions to improve SIT access and continuity of care. 
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Effect of Simvastatin on Transforming Growth Factor BETA-1-Induced Myofibroblast Differentiation and Collagen Production in Nasal Polyp-Derived Fibroblasts Il-Ho Park, MD, and Heung-man Lee, MD, PhD. Department of otorhinolaryngology-head and neck surgery, Korea university college of medicine, Seoul, South Korea. Background: Statins are the most commonly prescribed drugs for the treatment of hypercholesterolemia. Statins exert not only lipid-lowering but also other cellular effects, including anti-fibrotic properties. The purposes of this study were to determine the effect of simvastatin on Transforming growth factor (TGF)-b1-induced myofibroblast differentiation and collagen production in nasal polyp-derived fibroblasts (NPDFs) and to verify the mechanism of the effect of simvastatin in TGF-b1-induced myofibroblast differentiation in NPDFs. Methods: NPDFs were pre-treated with simvastatin with or without mevalonate or Y-27643 for 2 hours prior to induction by TGF-b1. The expression of a-smooth muscle actin (SMA) and collagen type IV mRNA was determined by a reverse transcription-polymerase chain reaction, and the expression of a-SMA protein was determined by immunofluoescent cytochemical staining. Total soluble collagen production was analyzed by the SirCol collagen dye-binding assay. Phosphorylation of Smad 2/3 was evaluated by Western blot analysis. Results: In TGF-b1-induced NPDFs, simvastatin significantly inhibited the expressions of a-SMA and collagen type IV mRNA and reduced a-SMA and collagen protein levels. Pre-treatment with mevalonate reversed the effect of simvastatin. The expression of a-SMA mRNA and protein was significantly decreased by pre-treatment with Y-27632. The TGF-b1-induced expression of pSmad 2/3 protein was notably decreased by pre-treatment with simvastatin. Conclusions: We showed that simvastatin inhibits TGF-b1-induced myofibroblast differentiation (expression of a-SMA) and collagen production in NPDFs and Rho/Rock and TGF-b/Smad signaling is involved as an underlying mechanism. The results of our study suggest that simvastatin is a possible candidate for the suppression of nasal polyp formation. Background: Ciclesonide hydrofluoroalkane nasal aerosol (CIC-HFA) is currently in development as a potential treatment for allergic rhinitis. The objective of this study was to determine the long-term safety and efficacy of CIC-HFA compared to placebo in subjects with perennial allergic rhinitis (PAR). Methods: Subjects $12 years of age with a $2 year history of PAR were randomized in a placebo-controlled, double-blind, parallel group, multicenter study to CIC-HFA 74 mg (N ¼ 298), CIC-HFA 148 mg (N ¼ 505), or placebo (N ¼ 307) QD AM for 26 weeks. Subject-reported change from baseline in reflective total nasal symptom score (rTNSS) and instantaneous total nasal symptom score (iTNSS) averaged every 2 weeks over the 26 weeks of the 
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